In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.
The in vitro activity of a new orally administered carbacephem analog of cefaclor, loracarbef (LY163892), was compared with those of cefaclor and several other oral antimicrobial agents against recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis. Loracarbef was found to be slightly more active than cefaclor against H. influenzae and had activity essentially equivalent to that of cefaclor for M. catarrhalis. Resistance to loracarbef was uncommon and was noted only with rare beta-lactamase-producing strains of H. influenzae. On the basis of these observations, loracarbef may be of utility in the management of localized, non-life-threatening infections caused by H. influenzae and M. catarrhalis.
Department of Clinical Microbiology, University of Massachusetts Medical Center, Worcester 01655.
G V
GV
Doern
R
R
Vautour
D
D
Parker
T
T
Tubert
B
B
Torres
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001424:Bacterial Infections / Q000382:microbiology; D002511:Cephalosporins / Q000494:pharmacology*; D006192:Haemophilus Infections / Q000382:microbiology; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000201:enzymology; D012141:Respiratory Tract Infections / Q000382:microbiology; D001618:beta-Lactamases / Q000032:analysis / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C054920:loracarbef; D001618:beta-Lactamases